{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T16:25:59Z","timestamp":1791563159174,"version":"4.3.4"},"reference-count":28,"publisher":"Walter de Gruyter GmbH","issue":"6","license":[{"start":{"date-parts":[[2021,4,15]],"date-time":"2021-04-15T00:00:00Z","timestamp":1618444800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100006483","name":"AbbVie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,6,25]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec id=\"j_jpem-2021-0114_abs_001_w2aab3b7c66b1b6b1aab1c15b1Aa\">\n                  <jats:title>Objectives<\/jats:title>\n                  <jats:p>Gonadotropin-releasing hormone agonist treatment is important for optimal growth in girls with central precocious puberty (CPP). Data are lacking regarding benefit to height outcome when treatment is started after chronological age (CA) of 7 years, and if continued beyond CA of 10 years or bone age (BA) of 12 years.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec id=\"j_jpem-2021-0114_abs_002_w2aab3b7c66b1b6b1aab1c15b2Aa\">\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Forty-eight girls with CPP were treated with monthly leuprolide depot. Change in predicted adult height (PAH) during treatment was assessed. Changes in PAH and growth velocity were compared between girls initiating treatment at CA &lt;7 vs.\u00a0\u22657 years, and BA\u00a0\u226512 vs. BA &lt;12 years.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec id=\"j_jpem-2021-0114_abs_003_w2aab3b7c66b1b6b1aab1c15b3Aa\">\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Mean baseline CA was 6.8 years, BA, 10.2 years; and PAH, 156.4\u00a0cm. BA\/CA ratio decreased from pretreatment values, averaging 1.5 to 1.2\u00a0at the end of treatment. Proportion of girls with &gt;5\u00a0cm PAH change during treatment was similar, and PAH increased throughout treatment in most girls, regardless of age at treatment initiation. PAH continued to increase in 16\/19 girls who continued treatment after BA of 12 years, and also in 16\/22 girls who continued treatment after CA of 10 years.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec id=\"j_jpem-2021-0114_abs_004_w2aab3b7c66b1b6b1aab1c15b4Aa\">\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>PAH improved in most girls who initiated treatment after CA of 7 years. It continued to improve in most girls with longer treatment, even past BA of 12 years or CA of 10 years, which suggests that no absolute CA or BA limit should define initiation or end of treatment. Treatment plans need to be individualized, and neither treatment initiation nor cessation should be based on BA or CA alone.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1515\/jpem-2021-0114","type":"journal-article","created":{"date-parts":[[2021,4,16]],"date-time":"2021-04-16T02:36:14Z","timestamp":1618540574000},"page":"733-739","source":"Crossref","is-referenced-by-count":15,"title":["Importance of individualizing treatment decisions in girls with central precocious puberty when initiating treatment after age 7 years or continuing beyond a chronological age of 10 years or a bone age of 12 years"],"prefix":"10.1515","volume":"34","author":[{"given":"Marcela","family":"Vargas Trujillo","sequence":"first","affiliation":[{"name":"Rady Children\u2019s Hospital , San Diego , CA , USA"},{"name":"Department of Pediatrics , University of California , San Diego , CA , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sanja","family":"Dragnic","sequence":"additional","affiliation":[{"name":"AbbVie , North Chicago , IL , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Petra","family":"Aldridge","sequence":"additional","affiliation":[{"name":"Covance, Inc. , Princeton , NJ , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen O.","family":"Klein","sequence":"additional","affiliation":[{"name":"Rady Children\u2019s Hospital , San Diego , CA , USA"},{"name":"Department of Pediatrics , University of California , San Diego , CA , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"374","published-online":{"date-parts":[[2021,4,15]]},"reference":[{"key":"2023040101193743225_j_jpem-2021-0114_ref_001_w2aab3b7c66b1b6b1ab2b2b1Aa","doi-asserted-by":"crossref","unstructured":"Lee, PA. Central precocious puberty. An overview of diagnosis, treatment, and outcome. Endocrinol Metab Clin N Am 1999;28:901\u201318, xi. https:\/\/doi.org\/10.1016\/s0889-8529(05)70108-0.","DOI":"10.1016\/S0889-8529(05)70108-0"},{"key":"2023040101193743225_j_jpem-2021-0114_ref_002_w2aab3b7c66b1b6b1ab2b2b2Aa","doi-asserted-by":"crossref","unstructured":"Carel, JC, Lahlou, N, Roger, M, Chaussain, JL. Precocious puberty and statural growth. Hum Reprod Update 2004;10:135\u201347. https:\/\/doi.org\/10.1093\/humupd\/dmh012.","DOI":"10.1093\/humupd\/dmh012"},{"key":"2023040101193743225_j_jpem-2021-0114_ref_003_w2aab3b7c66b1b6b1ab2b2b3Aa","doi-asserted-by":"crossref","unstructured":"Menon, PS, Vijayakumar, M. Precocious puberty\u2013perspectives on diagnosis and management. Indian J Pediatr 2014;81:76\u201383. https:\/\/doi.org\/10.1007\/s12098-013-1177-6.","DOI":"10.1007\/s12098-013-1177-6"},{"key":"2023040101193743225_j_jpem-2021-0114_ref_004_w2aab3b7c66b1b6b1ab2b2b4Aa","doi-asserted-by":"crossref","unstructured":"Carel, JC, Roger, M, Ispas, S, Tondu, F, Lahlou, N, Blumberg, J, et al.. Final height after long-term treatment with triptorelin slow release for central precocious puberty: importance of statural growth after interruption of treatment. French study group of Decapeptyl in Precocious Puberty. J Clin Endocrinol Metab 1999;84:1973\u20138. https:\/\/doi.org\/10.1210\/jcem.84.6.5647.","DOI":"10.1210\/jcem.84.6.5647"},{"key":"2023040101193743225_j_jpem-2021-0114_ref_005_w2aab3b7c66b1b6b1ab2b2b5Aa","doi-asserted-by":"crossref","unstructured":"Lebrethon, MC, Bourguignon, JP. Management of central isosexual precocity: diagnosis, treatment, outcome. Curr Opin Pediatr 2000;12:394\u20139. https:\/\/doi.org\/10.1097\/00008480-200008000-00020.","DOI":"10.1097\/00008480-200008000-00020"},{"key":"2023040101193743225_j_jpem-2021-0114_ref_006_w2aab3b7c66b1b6b1ab2b2b6Aa","doi-asserted-by":"crossref","unstructured":"Mul, D, Hughes, IA. The use of GnRH agonists in precocious puberty. Eur J Endocrinol 2008;159:S3\u20138. https:\/\/doi.org\/10.1530\/eje-08-0814.","DOI":"10.1530\/EJE-08-0814"},{"key":"2023040101193743225_j_jpem-2021-0114_ref_007_w2aab3b7c66b1b6b1ab2b2b7Aa","doi-asserted-by":"crossref","unstructured":"Carel, JC, Eugster, EA, Rogol, A, Ghizzoni, L, Palmert, MR, Group E-LGACC, et al.. Consensus statement on the use of gonadotropin-releasing hormone analogs in children. Pediatrics 2009;123:e752\u201362. https:\/\/doi.org\/10.1542\/peds.2008-1783.","DOI":"10.1542\/peds.2008-1783"},{"key":"2023040101193743225_j_jpem-2021-0114_ref_008_w2aab3b7c66b1b6b1ab2b2b8Aa","doi-asserted-by":"crossref","unstructured":"Eugster, EA, Clarke, W, Kletter, GB, Lee, PA, Neely, EK, Reiter, EO, et al.. Efficacy and safety of histrelin subdermal implant in children with central precocious puberty: a multicenter trial. J Clin Endocrinol Metab 2007;92:1697\u2013704. https:\/\/doi.org\/10.1210\/jc.2006-2479.","DOI":"10.1210\/jc.2006-2479"},{"key":"2023040101193743225_j_jpem-2021-0114_ref_009_w2aab3b7c66b1b6b1ab2b2b9Aa","doi-asserted-by":"crossref","unstructured":"Guaraldi, F, Beccuti, G, Gori, D, Ghizzoni, L. Management of endocrine disease: long-term outcomes of the treatment of central precocious puberty. Eur J Endocrinol 2016;174:R79\u201387. https:\/\/doi.org\/10.1530\/eje-15-0590.","DOI":"10.1530\/EJE-15-0590"},{"key":"2023040101193743225_j_jpem-2021-0114_ref_010_w2aab3b7c66b1b6b1ab2b2c10Aa","doi-asserted-by":"crossref","unstructured":"Kaplowitz, PB, Backeljauw, PF, Allen, DB. Toward more targeted and cost-effective gonadotropin-releasing hormone analog treatment in girls with central precocious puberty. Horm Res Paediatr 2018;90:1\u20137. https:\/\/doi.org\/10.1159\/000491103.","DOI":"10.1159\/000491103"},{"key":"2023040101193743225_j_jpem-2021-0114_ref_011_w2aab3b7c66b1b6b1ab2b2c11Aa","doi-asserted-by":"crossref","unstructured":"Mul, D, Oostdijk, W, Otten, BJ, Rouwe, C, Jansen, M, Delemarre-van de Waal, HA, et al.. Final height after gonadotrophin releasing hormone agonist treatment for central precocious puberty: the Dutch experience. J Pediatr Endocrinol Metab 2000;13:765\u201372. https:\/\/doi.org\/10.1515\/jpem.2000.13.s1.765.","DOI":"10.1515\/JPEM.2000.13.S1.765"},{"key":"2023040101193743225_j_jpem-2021-0114_ref_012_w2aab3b7c66b1b6b1ab2b2c12Aa","doi-asserted-by":"crossref","unstructured":"Partsch, CJ, Heger, S, Sippell, WG. Treatment of central precocious puberty: lessons from a 15 years prospective trial. German Decapeptyl Study Group. J Pediatr Endocrinol Metab 2000;13:747\u201358. https:\/\/doi.org\/10.1515\/jpem.2000.13.s1.747.","DOI":"10.1515\/JPEM.2000.13.S1.747"},{"key":"2023040101193743225_j_jpem-2021-0114_ref_013_w2aab3b7c66b1b6b1ab2b2c13Aa","doi-asserted-by":"crossref","unstructured":"Franzini, IA, Yamamoto, FM, Bolfi, F, Antonini, SR, Nunes-Nogueira, VS. GnRH analog is ineffective in increasing adult height in girls with puberty onset after 7 years of age: a systematic review and meta-analysis. Eur J Endocrinol 2018;179:381\u201390. https:\/\/doi.org\/10.1530\/eje-18-0473.","DOI":"10.1530\/EJE-18-0473"},{"key":"2023040101193743225_j_jpem-2021-0114_ref_014_w2aab3b7c66b1b6b1ab2b2c14Aa","doi-asserted-by":"crossref","unstructured":"Micillo, M, Salerno, M, Officioso, A, Perna, E, Gasparini, N, Pisaturo, L, et al.. Near final height after GnRH agonist treatment in central precocious puberty. J Pediatr Endocrinol Metab 2000;13:787\u201390. https:\/\/doi.org\/10.1515\/jpem.2000.13.s1.787.","DOI":"10.1515\/JPEM.2000.13.S1.787"},{"key":"2023040101193743225_j_jpem-2021-0114_ref_015_w2aab3b7c66b1b6b1ab2b2c15Aa","doi-asserted-by":"crossref","unstructured":"Oerter, KE, Manasco, P, Barnes, KM, Jones, J, Hill, S, Cutler, GBJr. Adult height in precocious puberty after long-term treatment with deslorelin. J Clin Endocrinol Metab 1991;73:1235\u201340. https:\/\/doi.org\/10.1210\/jcem-73-6-1235.","DOI":"10.1210\/jcem-73-6-1235"},{"key":"2023040101193743225_j_jpem-2021-0114_ref_016_w2aab3b7c66b1b6b1ab2b2c16Aa","doi-asserted-by":"crossref","unstructured":"Chen, M, Eugster, EA. Central precocious puberty: update on diagnosis and treatment. Paediatr Drugs 2015;17:273\u201381. https:\/\/doi.org\/10.1007\/s40272-015-0130-8.","DOI":"10.1007\/s40272-015-0130-8"},{"key":"2023040101193743225_j_jpem-2021-0114_ref_017_w2aab3b7c66b1b6b1ab2b2c17Aa","doi-asserted-by":"crossref","unstructured":"Klein, KO, Barnes, KM, Jones, JV, Feuillan, PP, Cutler, GBJr. Increased final height in precocious puberty after long-term treatment with LHRH agonists: the National Institutes of Health experience. J Clin Endocrinol Metab 2001;86:4711\u20136. https:\/\/doi.org\/10.1210\/jcem.86.10.7915.","DOI":"10.1210\/jcem.86.10.7915"},{"key":"2023040101193743225_j_jpem-2021-0114_ref_018_w2aab3b7c66b1b6b1ab2b2c18Aa","doi-asserted-by":"crossref","unstructured":"Neely, EK, Lee, PA, Bloch, CA, Larsen, L, Yang, D, Mattia-Goldberg, C, et al.. Leuprolide acetate 1-month depot for central precocious puberty: hormonal suppression and recovery. Int J Pediatr Endocrinol 2010;2010:398639. https:\/\/doi.org\/10.1186\/1687-9856-2010-398639.","DOI":"10.1186\/1687-9856-2010-398639"},{"key":"2023040101193743225_j_jpem-2021-0114_ref_019_w2aab3b7c66b1b6b1ab2b2c19Aa","unstructured":"Tanner, J. Growth at adolescence. With a general consideration of the effects of hereditary and environmental factors upon growth and maturation from birth to maturity, 2nd ed. Oxford, UK: Blackwell Scientific; 1962."},{"key":"2023040101193743225_j_jpem-2021-0114_ref_020_w2aab3b7c66b1b6b1ab2b2c20Aa","unstructured":"Roche, AF, Chumlea, WC, Thissen, D. Assessing the skeletal maturity of the hand-wrist: FELS method. Springfield, IL: Charles C Thomas Pub Ltd; 1988."},{"key":"2023040101193743225_j_jpem-2021-0114_ref_021_w2aab3b7c66b1b6b1ab2b2c21Aa","doi-asserted-by":"crossref","unstructured":"Bayley, N, Pinneau, SR. Tables\u00a0for predicting adult height from skeletal age: revised for use with the Greulich-Pyle hand standards. J Pediatr 1952;40:423\u201341.","DOI":"10.1016\/S0022-3476(52)80205-7"},{"key":"2023040101193743225_j_jpem-2021-0114_ref_022_w2aab3b7c66b1b6b1ab2b2c22Aa","doi-asserted-by":"crossref","unstructured":"Li, P, Li, Y, Yang, CL. Gonadotropin releasing hormone agonist treatment to increase final stature in children with precocious puberty: a meta-analysis. Medicine 2014;93:e260. https:\/\/doi.org\/10.1097\/md.0000000000000260.","DOI":"10.1097\/MD.0000000000000260"},{"key":"2023040101193743225_j_jpem-2021-0114_ref_023_w2aab3b7c66b1b6b1ab2b2c23Aa","doi-asserted-by":"crossref","unstructured":"Nabhan, ZM, Feezle, LK, Kunselman, AR, Johnson, NB, Lee, PA. Normal adult height among girls treated for central precocious puberty with gonadotropin-releasing hormone analog therapy. J Pediatr Endocrinol Metab 2009;22:309\u201316. https:\/\/doi.org\/10.1515\/jpem.2009.22.4.309.","DOI":"10.1515\/JPEM.2009.22.4.309"},{"key":"2023040101193743225_j_jpem-2021-0114_ref_024_w2aab3b7c66b1b6b1ab2b2c24Aa","doi-asserted-by":"crossref","unstructured":"Poomthavorn, P, Suphasit, R, Mahachoklertwattana, P. Adult height, body mass index and time of menarche of girls with idiopathic central precocious puberty after gonadotropin-releasing hormone analogue treatment. Gynecol Endocrinol 2011;27:524\u20138. https:\/\/doi.org\/10.3109\/09513590.2010.507289.","DOI":"10.3109\/09513590.2010.507289"},{"key":"2023040101193743225_j_jpem-2021-0114_ref_025_w2aab3b7c66b1b6b1ab2b2c25Aa","doi-asserted-by":"crossref","unstructured":"Arrigo, T, Cisternino, M, Galluzzi, F, Bertelloni, S, Pasquino, AM, Antoniazzi, F, et al.. Analysis of the factors affecting auxological response to GnRH agonist treatment and final height outcome in girls with idiopathic central precocious puberty. Eur J Endocrinol 1999;141:140\u20134. https:\/\/doi.org\/10.1530\/eje.0.1410140.","DOI":"10.1530\/eje.0.1410140"},{"key":"2023040101193743225_j_jpem-2021-0114_ref_026_w2aab3b7c66b1b6b1ab2b2c26Aa","doi-asserted-by":"crossref","unstructured":"Bereket, A. A critical appraisal of the effect of gonadotropin-releasing hormone analog treatment on adult height of girls with central precocious puberty. J Clin Res Pediatr Endocrinol 2017;9:33\u201348. https:\/\/doi.org\/10.4274\/jcrpe.2017.S004.","DOI":"10.4274\/jcrpe.2017.S004"},{"key":"2023040101193743225_j_jpem-2021-0114_ref_027_w2aab3b7c66b1b6b1ab2b2c27Aa","doi-asserted-by":"crossref","unstructured":"Bertelloni, S, Massart, F, Einaudi, S, Wasniewska, M, Miccoli, M, Baroncelli, GI. Central precocious puberty: adult height in girls treated with quarterly or monthly gonadotropin-releasing hormone analog triptorelin. Horm Res Paediatr 2015;84:396\u2013400. https:\/\/doi.org\/10.1159\/000441497.","DOI":"10.1159\/000441497"},{"key":"2023040101193743225_j_jpem-2021-0114_ref_028_w2aab3b7c66b1b6b1ab2b2c28Aa","doi-asserted-by":"crossref","unstructured":"Lee, HS, Yoon, JS, Park, KJ, Hwang, JS. Increased final adult height by gonadotropin-releasing hormone agonist in girls with idiopathic central precocious puberty. PloS One 2018;13:e0201906. https:\/\/doi.org\/10.1371\/journal.pone.0201906.","DOI":"10.1371\/journal.pone.0201906"}],"container-title":["Journal of Pediatric Endocrinology and Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.degruyter.com\/document\/doi\/10.1515\/jpem-2021-0114\/xml","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.degruyter.com\/document\/doi\/10.1515\/jpem-2021-0114\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T19:25:21Z","timestamp":1680377121000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.degruyter.com\/document\/doi\/10.1515\/jpem-2021-0114\/html"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4,15]]},"references-count":28,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2021,4,6]]},"published-print":{"date-parts":[[2021,6,25]]}},"alternative-id":["10.1515\/jpem-2021-0114"],"URL":"https:\/\/doi.org\/10.1515\/jpem-2021-0114","relation":{},"ISSN":["2191-0251","0334-018X"],"issn-type":[{"value":"2191-0251","type":"electronic"},{"value":"0334-018X","type":"print"}],"subject":[],"published":{"date-parts":[[2021,4,15]]}}}